Up­dat­ed: Mile­stone Phar­ma claims PhI­II re­demp­tion for its once-failed heart drug, putting it on a path to the FDA

More than two years af­ter Mile­stone Phar­ma­ceu­ti­cals’ stock got ham­mered af­ter their lead heart drug flopped in a cru­cial Phase III study, the biotech is look­ing for some re­demp­tion now that its re­designed Phase III piv­otal has come through with pos­i­tive re­sults.

Mile­stone went pub­lic $MIST back in 2019 on the back of a plan to cre­ate a self-ad­min­is­tered nasal spray ver­sion of a cal­ci­um chan­nel block­er to treat cas­es of parox­ys­mal supraven­tric­u­lar tachy­car­dia (PSVT) — non­fa­tal bursts of heart rate that of­ten send pa­tients run­ning to the ER.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER